Nanoparticle Contract Manufacturing Services Market Size, Share, and Industry Analysis, By Type (Lipid, Metal, and Others), By Application (Therapeutics, Diagnostics, and Others), By Manufacturing Scale (Pre-clinical, Clinical, and Commercial), By End-user (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, and Others), and Regional Forecast, 2024-2032

Nanoparticle contract manufacturing refers to the services provided to companies for the production and utilization of nanoparticles in various applications. These services typically involve the design, synthesis, characterization, and scale-up production of nanoparticles for usage in industries, such as pharmaceuticals, biotechnology, and others.

Nanoparticles such as lipids, metals, and polymers have a significant role in biomedicine applications. Lipid nanoparticles are used as carriers in the gene delivery systems used to deliver nucleic acids, making them promising vectors for various therapeutic applications in the pharmaceutical industry. The metal nanoparticles are used in magnetic resonance imaging (MRI) contrast agents, wound dressing, tissue engineering, and hyperthermia therapy.

The market for nanoparticle contract manufacturing is expected to grow significantly, driven by the increasing demand for advanced materials with unique properties and applications. Nanoparticles offer significant advantages such as improved drug delivery, increased stability, enhanced optical and magnetic properties, and other benefits. As a result, several companies are increasingly turning toward contract manufacturing with expertise in nanoparticle development and manufacturing to help them bring innovative products to the market.

Additionally, the development of production technologies and players’ constant initiatives to expand their services are expected to drive market growth in the forecast period. Moreover, strategic initiatives such as the incorporation of new services and acquisitions by key players are expected to drive the market.

• For instance, in October 2022, Polypeptide Therapeutic Solutions (PTS), the manufacturer of polyamino-acid-based delivery systems, expanded its capabilities, including functional lipid excipients and novel nanoparticle formulation.

The COVID-19 pandemic positively impacted the market in 2020 due to the related demand. Furthermore, in 2021, the market witnessed growth primarily driven by the adoption of lipid nanoparticles as carriers for vaccine delivery. Companies, such as Pfizer Inc. and Moderna, Inc. used these nanoparticle technologies to produce the mRNA COVID-19 vaccines, highlighting their crucial role in vaccine development.

Segmentation

Key Insights

The report covers the following key insights:

• Overview: Biomedical Applications of Nanoparticles


• Regulatory Scenario for Key Countries/Regions


• Key Industry Developments (Partnerships, Mergers, and Acquisitions)


• Impact of COVID-19 on the Market

Analysis by Type

Based on type, the market is classified into lipid, metal, and others. The lipid segment held significant revenue in 2023. The segment growth is attributed to increasing demand for the mRNA-based vaccines for lipid nanoparticles as the delivery systems, and the advancements in lipid nanoparticle production technologies. These factors increase the demand for outsourcing for vaccine development and gene therapies, which is expected to drive this services segment significantly.

• For instance, in October 2021, Gattefossé, a Contract Manufacturing company, incorporated three new advanced lipid excipients, including Emulfree Duo, Labrafac MC60, Gelucire, and, to expand the delivery of unique customer solutions.

The metal segment is expected to grow at a significant CAGR in the coming years. The increasing use of metal nanoparticles for cancer treatment and diagnostics is a major factor that is expected to drive the market growth. This increased use of metal nanoparticles in cancer therapeutics increases the demand for contract manufacturing services for the formulation of drugs.

Regional Analysis

To gain extensive insights into the market, Request for Customization

The global market is geographically segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America held a significant revenue in 2023. The presence of a thriving pharmaceutical and biotechnology industry drives the demand for nanoparticle contract manufacturing services in North America. Additionally, the region’s R&D initiatives and new product launches using the nanoparticles as the carriers are expected to drive the market. Advancements such as the use of polymers, peptides, protamine, and lipids nanoparticles for the delivery of mRNA vaccines and growth in cancer and gene therapies are increasing the demand for nanoparticle contract manufacturing services in the region. Moreover, the region’s players’ focus on the expansion of their contract manufacturing services for the lipid and metal nanoparticles could potentially drive the market.

• For instance, in May 2022, Gattefossé opened a new manufacturing facility in Texas, U.S., to produce lipid-based specialty ingredients for the pharmaceutical and cosmeceutical industries.

On the other hand, the Asia Pacific region is expected to grow faster in the coming years. The increasing investments in the pharmaceutical and biotechnology sectors in countries such as China and India drive the demand for nanoparticle contract manufacturing services in Asia. Additionally, the companies are investing in research and development to enhance their capabilities in nanoparticle contract manufacturing services. These factors are expected to drive the region’s market growth.

Key Players Covered

The report includes key players, such as Fortis Life Sciences, Baxter, Merck KGaA, Evonik, DPT Laboratories, LTD., FUJIFILM Corporation, and Renejix Pharma Solutions.

Key Industry Developments

• In March 2022, eTheRNA Manufacturing launched novel liquid nanoparticle formulation development and production services. The service enables accurate and customized distribution of substances through the use of eTheRNA’s distinct lipid libraries and formulations.


• In February 2022, Merck KGaA acquired Exelead for its lipid nanoparticle drug delivery technology to expand the company’s contract manufacturing services.


• In January 2019, Cambrex Corporation, a manufacturer of small molecule API & finished dosage forms, acquired Avista Pharma Solutions to expand its contract manufacturing services, including nanoparticle production.